

		(₹ in lakhs)	
Particulars		31 March 2019	31 March 2018
(vii) Sensitivity analysis for gratuity			
a) Impact of the change in discount rate			
Present value of obligation at the end of the year		2,399.05	2,043.98
Impact due to increase of 0.50 %		(86.42)	(76.65)
Impact due to decrease of 0.50 %		93.49	83.10
b) Impact of the change in salary increase			
Present value of obligation at the end of the year		2,399.05	2,043.98
Impact due to increase of 0.50 %		95.49	84.98
Impact due to decrease of 0.50 %		(88.93)	(78.97)

Sensitivities due to mortality and withdrawals are not material. Hence impact of change is not calculated above.

Sensitivities as to rate of inflation, rate of increase of pensions in payment, rate of increase of pensions before retirement and life expectancy are not applicable being a lump sum benefit on retirement.

The above sensitivity analysis is based on a change in an assumption while holding all other assumptions constant. In practice, this is unlikely to occur, and changes in sum of the assumptions may be correlated. When calculating the sensitivity of defined benefit obligation to significant actuarial assumptions the same method (present value of defined benefit obligations calculated with the projected unit credit method at the end of the reporting period) has been applied as when calculating the defined benefit liability recognised in the balance sheet.

(viii) Risk

Salary increases	Actual salary increases will increase the Plan's liability. Increase in salary increase rate assumption in future valuations will also increase the liability.
Discount rate	Reduction in discount rate in subsequent valuations can increase the plan's liability.
Mortality and disability	Actual deaths & disability cases proving lower or higher than assumed in the valuation can impact the liabilities.
Withdrawals	Actual withdrawals proving higher or lower than assumed withdrawals and change of withdrawal rates at subsequent valuations can impact Plan's liability.

Note - 43

Share based payments

GHPL ESOP Plan 2014

The Holding Company vide General Meeting resolution dated 25 September 2014 approved "Global Health Employee Stock Option Scheme 2014" for granting employee stock options in the form of equity shares linked to the completion of a minimum period of continued employment to the eligible employees of the Holding Company. The plan was modified on 11 May 2016 where in the Holding Company increased the number of available options from 740,628 to 852,973 to eligible employees and the vesting period was changed from 5 years from the date of grant to graded vesting of 25% each year starting with effect from 30 April 2016. The Holding Company had granted 740,628 options to eligible employees on 25 September 2014. The eligible employees, including directors, for the purpose of this scheme will be determined by the Remuneration Committee from time to time. Each stock options entitle the eligible employee to avail one share at the end of the vesting period. The vested options can be exercised within a period of 3 years from the date of vesting.

Movement in number of options:

Particulars	As at 31 March 2019	As at 31 March 2018
Opening balance	844,824	844,824
Exercised during the year	454,974	-
Lapsed during the year	35,638	-
Closing balance	354,212	844,824

Particulars	Grant I	Grant II	Grant III	Grant IV
Outstanding options	581,920	26,451	26,451	210,000
Grant date	25 September 2014	13 July 2016	9 November 2016	10 December 2016
Vesting period	Graded vesting (25% options to vest every year from the date of grant)	Graded vesting (25% options to vest every year from the date of grant)	Graded vesting (25% options to vest every year from the date of grant)	Graded vesting (25% options to vest every year from the date of grant)
Exercise price	10.00	10.00	10.00	10.00
Expiry Date	29 April 2022	12 July 2023	08 November 2023	09 December 2023
Fair value of option on the date	691.95	742.28	755.29	755.24
Remaining contractual life (weighted months)	2.48	4.28	4.61	4.70

*The fair value of the options has been determined using the Black Scholes model, as certified by an independent valuer with the following assumptions:

Particulars	Grant I	Grant II	Grant III	Grant IV
Weighted average share price (Rs.)	698.65	749.78	762.95	762.95
Exercise price (Rs.)	10.00	10.00	10.00	10.00
Expected volatility (%)	37%	37%	37%	36%
Expected life of the option (years)	4.7	4.7	4.7	4.7
Expected dividend yield	-	-	-	-
The risk-free interest rate	8.70%	7.18%	6.67%	6.51%
Weighted average fair value as on the grant date (Rs.)	691.95	742.28	755.29	755.24



GHPL ESOP Plan 2016

The Holding Company vide General Meeting resolution dated 13 July 2016 approved "Global Health Employee Stock Option Scheme 2016" for granting employee stock options in the form of equity shares linked to the completion of a minimum period of continued employment to the eligible employees of the Holding Company. The eligible employees, including directors, for the purpose of this scheme will be determined by the Remuneration Committee from time to time. Each stock option entitle the eligible employee to avail one share at the end of the vesting period. The authorized share capital of the Company was also increased by creation of 1,025,000 Class A equity shares on 13 July 2016 with a view to allot the shares under the ESOP Plan 2016. The vested options can be exercised within a period of 3 years from the date of vesting.

Movement in number of options:

Particulars	As at 31 March 2019	As at 31 March 2018
Opening balance	615,000	535,000
Exercised during the year	183,750	-
Granted during the year	340,000	80,000
Closing balance	771,250	615,000

Particulars	Grant I	Grant II	Grant III	Grant IV	Grant V
Option granted	535,000.00	80,000	50,000	50,000	240,000
Grant date	10 December 2016	19 March 2018	17 April 2018	25 April 2018	13 July 2018
Vesting period	Graded vesting (25% options to vest every year from the date of grant)	Graded vesting (25% options to vest every year from the date of grant)	Graded vesting (33.33% options to vest every year from the date of grant)	Graded vesting (33.33% options to vest every year from the date of grant)	Graded vesting (20% options to vest every year from the date of grant)
Exercise price	10.00	10.00	10.00	10.00	10.00
Expiry date	09 December 2023	19 March 2025	15 April 2024	23 April 2024	11 July 2026
Fair market value of option on the date of grant*	755.24	633.44	626.03	626.16	626.17
Remaining contractual life (weighted months)	4.70	5.97	6.05	6.07	6.28

*The fair value of the options has been determined using the black Scholes model, as certified by an independent valuer with the following assumptions

Particulars	Grant I	Grant II	Grant III	Grant IV	Grant V
Weighted average share price (Rs.)	762.95	633.44	633.44	633.44	633.44
Exercise price (Rs.)	10.00	10.00	10.00	10.00	10.00
Expected volatility (%)	36%	37%	37.60%	37.76%	37.33%
Expected life of the option (years)	4.7	4.7	4.6	4.6	4.8
Expected dividend yield	-	-	-	-	-
The risk-free interest rate	6.51%	7.44%	8.09%	7.82%	8.22%
Weighted average fair value as on the grant date (Rs.)	755.24	633.44	626.03	626.16	626.17

During the year ended on 31 March 2019 and 31 March 2018, the Company has recorded an employee stock compensation expense of ₹ 2,603.07 lakhs and ₹ 3,196.43 lakhs respectively.

During the year ended on 31 March 2019, the total number of options vested but not exercised is 216,667 (31 March 2018 : 344,942).

The weighted average share price on the date of exercise is ₹ 627.18.

Note - 44

The chief operating decision maker (CODM) (i.e. Chairman & Managing Director and Chief Finance Officer) examines the Group's performance from a product perspective and has identified the Healthcare services as single business segment. The Group is operating in India which constitutes a single geographical segment. The CODM reviews internal management reports to assess the performance of the segment 'Healthcare services'.

The revenues from external customers attributed to an individual is not material and there are no transactions with a single external customer amount to ten percent or more of the Group's revenues.

Note - 45

Research and development expenditure includes Consultant's and Specialist honorarium amounting to ₹ 2.78 lakhs (31 March 2018: ₹ 2.07 lakhs) and salaries of employees amounting to ₹ 127.77 lakhs (31 March 2018: ₹ 153.19 Lakhs).

Handwritten signature



Note - 46

The Holding Company is the legal owner of Freehold land situated in Medicity site located in Sector 38, Gurgaon. The Holding Company had entered into a Joint Development Agreement (JDA) with Global Infracon Private Limited (GIPL) on 2 August 2007, for the development of the Support Area (a portion of Freehold land of 5 acres). Pursuant to said agreement the Holding Company also entered into support area service agreement (SSA) whereby SAS Infotech Private Limited assumed all the obligations towards the construction of support area, liabilities towards allottees in place of GIPL and also agreed to provide 30,000 square feet to the Company. In the earlier years, the Holding Company has exercised its option to release 30,000 square feet of area to GIPL for an agreed consideration of ₹ 3,300 Lakhs which is recognised as income and charged off the proportionate cost of land of ₹ 836.85 Lakhs. The Holding Company, GIPL and SAS had certain differences under JDA and SAS and hence, with a view to ensure harmonious business relation between the parties, the Holding Company had paid ₹ 1,000 lakhs in the year ended 31 March 2018 as full and final settlement, which had been charged off to the statement of profit and loss and presented as compensation paid under the head other expenses.

Note - 47

Amalgamation of Dr. Naresh Trehan & Associates Health Services Private Limited, (referred to as 'transferor company') with Global Health Private Limited ('transferee company' or 'the Company');

- (i) The Hon'ble National Holding Company Law Tribunal of New Delhi vide its order dated 16 February 2018 approved the scheme of amalgamation (the Scheme) of the transferor Holding Company with the Holding Company. The same has been filed with Registrar of Companies on 6 March 2018 and hence, the Scheme became effective from this date. The appointed date of the scheme is 1 April 2016.
- (ii) The Holding Company is engaged in the business of providing healthcare services whereas the transferor Holding Company was acting as an investment holding special purpose vehicle.
- (iii) These financial statements have been prepared after giving effect to the Scheme and accordingly, transferor Holding Company has been amalgamated with the Holding Company, after incorporating the following adjustments:
- Elimination of inter-company transactions between the Holding Company and the transferor Company as of and for the year ended 31 March 2018; and
 - Cancellation and extinguishment of share capital of transferor company and cancellation of investment in the share capital of the Holding Company held by the transferor company pursuant to the said Scheme.
- (iv) In connection with the Scheme:
- All the assets, liabilities, rights, powers and duties of the transferor company were vested in the Holding Company as a going concern from the effective date and the transferor company without any further act was dissolved without winding up.
 - Pursuant to the Scheme coming into effect, the authorized share capital of the transferor company will be combined and resultantly there will be an increase in authorized equity share capital of the Company by ₹ 5,000 lakhs.
 - The difference between the net assets of the transferor company taken over by the Holding Company and the consideration is recognised in capital reserve.
 - The value of assets and liabilities taken under the Scheme and the treatment of excess/shortfall thereof, if any is presented below :

Particulars	(₹ in lakhs)	
	Transferor company	
Assets taken over		
Cash and cash equivalents		0.18
Total (B)		0.18
Liabilities		
Other equity (retained earnings balance)		(80.90)
Other financial liabilities		61.08
Total (A)		(19.82)
Net assets taken over (C) = (B - A)		20.00
Share capital of transferor companies extinguished and cancelled (D)		-
Net impact presented as capital reserve (C - D)		20.00

Note - 48

Pursuant to the recent judgement by the Hon'ble Supreme Court of India dated 28 February 2019, the meaning of "basic wages" was interpreted for the purpose of Employees' Provident Fund Act, 1952. However, there is uncertainty with respect to the period of applicability of the judgement. Accordingly, as a matter of abundant caution, the Holding Company has made a provision on prospective basis in line with the said judgement.

[Handwritten signature]

(This space has been intentionally left blank)



Note - 49
Interest in subsidiaries and joint venture

(a) Subsidiaries

Name of entity	Place of business	Ownership interest held by the Group (%)		Ownership interest held by non-controlling interest (%)		Principal activities
		As at 31 March 2019	As at 31 March 2018	As at 31 March 2019	As at 31 March 2018	
Global Health Padiputra Private Limited	India	100	100	-	-	Healthcare services
Medanta Holdings Private Limited (refer note 50)	India	100	100	-	-	Healthcare services

(b) Joint venture (equity method)

(₹ in lakhs)

Name of entity	Place of business	% of ownership interest	Accounting method	Carrying amount	
				As at 31 March 2019	As at 31 March 2018
Medanta Duke Research Institute Private Limited	India	50.01%	Equity Method	-	484.01

* Joint venture company is engaged in the business to undertake clinical research and trial, including controlled medical studies of novel therapeutic interventions.

(i) There were no commitments and contingent liabilities in joint venture company.

(ii) Summarised financial information for joint venture

(₹ in lakhs)

Summarised balance sheet	Medanta Duke Research Institute Private Limited	
	As at 31 March 2019	As at 31 March 2018
Current assets		
Cash and cash equivalents	1.28	6.20
Other assets	7.57	0.87
Total current assets (A)	8.85	7.07
Total non-current assets (B)	1.31	65.06
Assets held for sale (C)	54.75	-
Total assets (D = A+B+C)	64.91	72.12
Current liabilities		
Financial liabilities (excluding trade payables)	-	3.13
Other liabilities (including trade payables)	2.79	0.41
Total current liabilities (E)	2.79	3.54
Non-current liabilities		
Financial liabilities	-	-
Other liabilities	-	1.31
Total non-current liabilities (F)	-	1.31
Total liabilities (G = E+F)	2.79	4.86
Net assets (D-G)	62.12	67.27

Reconciliation to carrying amount of investment

Summarised balance sheet	Medanta Duke Research Institute Private Limited	
	As at 31 March 2019	As at 31 March 2018
Opening retained earnings	(835.45)	(821.61)
Loss for the year	(5.16)	(13.93)
Other comprehensive income	-	0.09
Closing net assets	(840.61)	(835.45)
Group's share in %	50.01%	50.01%
Group's share in ₹	(420.39)	(417.81)
Gross value of investment	901.80	901.80
Carrying value of investment	481.43	484.01
Less: Impairment in the value of investment	(481.43)	-
Net carrying value of investment	-	484.01

(This space has been intentionally left blank)



Global Health Private Limited

Notes to the consolidated financial statements for the year ended 31 March 2019

Note - 50

Business combinations

Background of transaction

The Group had acquired 100% equity stake (with voting interests) in Medanta Holdings Private Limited (final acquisition date is 26 February 2018), which is engaged in business of healthcare services. The acquisition was made to enhance the Group's position in healthcare services in the central region of India.

Details of assets and liabilities acquired of the acquiree entities

The fair values of the identifiable assets and liabilities of as at the date of acquisition were:

(₹ in lakhs)

Assets acquired and liabilities assumed	Medanta Holdings Private Limited
Property, plant and equipment	16,072.81
Capital work-in-progress	23,845.78
Other non-current assets	1,109.12
Cash and cash equivalents	1,213.47
Other bank balances	280.38
Other current assets	7.28
Total assets	42,528.84
Compulsorily convertible preference shares*	5,000.00
Other non-current liabilities	23.25
Other current financial and non-financial liabilities	21,154.77
Other current liabilities	28.08
Total liabilities	26,206.10
Net identifiable assets acquired	16,322.74
Fair value of purchase consideration transferred	15,150.00
Capital reserve	(1,172.74)

* These were converted into equity shares in the month of March 2018

Cash flow on acquisition

(₹ in lakhs)

Particulars	Amount
Purchase consideration - equity shares	9,250.99
Purchase consideration - compulsorily convertible preference shares*	5,899.01
Net cash outflow on acquisition	15,150.00

* These were converted into equity shares in the month of March 2018

Acquisition related costs

The Group has incurred acquisition related costs of ₹ 2 lakhs and are included in other expenses in statement of profit and loss.

Contribution to the group results

Medanta Holdings Private Limited has contributed ₹ 1.91 lakhs of other income and ₹ (11.51) lakhs to loss before tax since 26 February 2018 to 31 March 2018. Had the acquisition taken place at the beginning of year i.e. 01 April 2017, the Group's revenue would have been ₹ 139,294.06 lakhs and the profit before tax would have been ₹ 5,866.76 lakhs.

[Handwritten signature]

(This space has been intentionally left blank)




Global Health Private Limited
Notes to the consolidated financial statements for the year ended 31 March 2019

Note - 51
Additional disclosure required under Schedule III of the Companies Act 2013 of the entities consolidated as subsidiaries and joint venture --

Name of the entity	Net assets i.e. total assets minus total liabilities		Share in statement of profit and loss		Share in other comprehensive income		Share in total comprehensive income	
	As % of Consolidated net assets	Amount (₹ in lakhs)	As % of Consolidated profit	Amount (₹ in lakhs)	As % of Consolidated other comprehensive income	Amount (₹ in lakhs)	As % of Consolidated total comprehensive income	Amount (₹ in lakhs)
Holding Company								
Global Health Private Limited	101.05%	131,884.71	108.57%	6,714.12	99.52%	31.88	108.92%	6,325.64
Subsidiaries								
Indian								
Global Health Patliputra Private Limited	-1.50%	(1,699.67)	-7.64%	(473.48)	0.00%	-	-8.15%	(473.48)
Medians Holdings Private Limited (refer note 49)	-0.11%	(149.49)	-0.68%	(42.55)	0.48%	0.15	-0.73%	(42.19)
Joint venture (investment accounted for using the equity method)								
Indian								
Medians Duha Research Institute Private Limited	0.36%	481.43	-0.03%	(2.58)	0.00%	-	-0.04%	(2.58)
Total	100%	130,516.98	100%	6,195.71	100%	32.02	100%	5,807.39

(This space has been intentionally left blank)



Note - 52

Revenue related disclosures

I Disaggregation of revenue

Revenue recognised mainly comprises of healthcare services. Set out below is the disaggregation of the Group's revenue from contracts with customers:

(₹ in lakhs)	
Description	For the year ended 31 March 2019
(A) Operating revenue	
Income from healthcare services	
In patient	116,807.36
Out patient	26,875.98
(B) Other operating revenue	
Clinical research income	251.33
Other operating revenue	178.55
Total revenue	144,113.22

(₹ in lakhs)	
Description	For the year ended 31 March 2019
(A) Operating revenue	
Income from healthcare services	
Government	17,820.91
Non-government	125,862.43
Total operating revenue	143,683.34

II Contract balances

The following table provides information about receivables and contract liabilities from contract with customers:

(₹ in lakhs)	
Particulars	As at 31 March 2019
Contract liabilities	
Advance from customers	1,609.61
Total contract liabilities	1,609.61
Contract assets	
Unbilled revenue	1,082.11
Total contract assets	1,082.11

Contract asset is the right to consideration in exchange for goods or services transferred to the customer. Contract liability is the entity's obligation to transfer goods or services to a customer for which the entity has received consideration from the customer in advance. Contract assets (unbilled receivables) are transferred to receivables when the rights become unconditional and contract liabilities are recognised as and when the performance obligation is satisfied.

III Significant changes in the contract liabilities balances during the year are as follows:

(₹ in lakhs)	
Contract liabilities - Advance from customers	As at 31 March 2019
Opening balance of Contract liabilities - Advance from customers	2,045.23
Less: Amount of revenue recognised during the year	(143,683.34)
Add: Addition during the year	143,247.72
Closing balance of Contract liabilities - Advance from customers	1,609.61

The aggregate amount of transaction price allocated to the performance obligations (yet to complete) as at 31 March 2019 is ₹ 1,609.61 lakhs. This balance represents the advance received from customers (gross) against healthcare services. The management expects to further bill and collect the remaining balance of total consideration in the coming period. These balances will be recognised as revenue in subsequent period as per the policy of the Group.



Note - 53

Previous year figures have been regrouped/reclassified, where necessary, to confirm to this year's classification, as below -

(₹ in lakhs)

Balance Sheet	31 March 2018 (Reported)	Adjustments	31 March 2018 (Reclassified)
Non-current assets			
Financial assets			
Other financial assets	2,319.64	230.20	2,549.84
Deferred tax assets (net)	-	0.29	0.29
Other non-current assets	2,731.73	(0.33)	2,731.40
Current assets			
Financial assets			
Other bank balances	21,588.43	(230.20)	21,358.23
Other current assets	1,300.34	21.07	1,321.41
Non-current liabilities			
Deferred tax liabilities (net)	4,807.60	(0.04)	4,807.56
Current liabilities			
Financial liabilities			
Other financial liabilities	9,278.34	170.21	9,448.55
Other current liabilities	4,059.80	(149.14)	3,910.66

For Walker Chandick & Co LLP
 Chartered Accountants
 Firm's Registration No.: 001076N/N500013

Siddharth Talwar
 Siddharth Talwar
 Partner
 Membership No.: 512752

Place: Gurugram
 Date: 26 September 2019



For and on behalf of the Board of Directors

Archer
 Chairman and Managing Director
 [DIN:00012148]
Sajit K
 Chief Financial Officer

[Signature]
 Chief Executive Officer
[Signature]
 Company Secretary